8
Views
9
CrossRef citations to date
0
Altmetric
Cell Growth and Development

Cyclosporin A Promotes Translational Silencing of Autocrine Interleukin-3 via Ribosome-Associated Deadenylation

, , &
Pages 889-898 | Received 02 Mar 1998, Accepted 04 Sep 1998, Published online: 28 Mar 2023
 

Abstract

Translation is regulated predominantly by an interplay between cis elements at the 3′ and 5′ ends of mRNAs and trans-acting proteins. Cyclosporin A (CsA), a calcineurin antagonist and blocker of interleukin-2 (IL-2) transcription in T cells, was found to inhibit translation of IL-3 mRNA in autocrine mast cell tumor lines. The mechanism involved ribosome-associated poly(A) shortening and required an intact AU-rich element in the 3′ untranslated region. FK506, another calcineurin inhibitor, shared the effect. The translational inhibition by CsA was specific to oncogenically induced lymphokines IL-3 and IL-4 but not to IL-6, c-jun, and c-myc, which are expressed in the nonmalignant precursor cells. Furthermore, no translational down-regulation of the mRNA was observed in IL-3-transfected precursor cells. These data suggest that translational silencing is associated with the tumor phenotype.

ACKNOWLEDGMENTS

We thank George Thomas, Harold Jeffries, and Witold Filipowicz for advice; Adrian Wyss, Lyndall Brennan, and Corina Gyssler-Frey for technical assistance; members of the laboratory for their comments on the manuscript; and Nicole Vehlinger for secretarial assistance.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.